Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Aug. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI

Market Cap	304M 262M 247M 224M 422M 29.1B 428M 2.89B 1.13B 14.55B 1.14B 1.12B 48.47B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	400M 345M 325M 295M 555M 38.3B 563M 3.81B 1.49B 19.16B 1.5B 1.47B 63.81B	EV / Sales 2026 *	-	EV / Sales 2027 *	11x
Free-Float	96.87%	Yield 2026 *	-	Yield 2027 *	-

Aug. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
May. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
Apr. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Nov. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
25-10-31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
25-10-26	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
25-10-23	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
25-08-26	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

Aug. 14	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
Aug. 06	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
Jul. 02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
May. 15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31

Northwest Biotherapeutics, Inc Stock OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.17%	+4.35%	+72.39%	+114.97%	73.45B
ARGENX SE	+0.34%	+14.77%	+56.24%	+91.49%	62.99B
INSMED INCORPORATED	+0.11%	-3.10%	+0.94%	+491.16%	28.05B
WUXI BIOLOGICS (CAYMAN) INC.	-1.52%	+4.77%	+60.78%	+20.30%	25.42B
BIONTECH SE	+1.26%	-0.05%	-17.59%	-15.96%	23.3B
GENMAB A/S	+0.90%	+4.17%	+40.02%	-14.95%	19.45B
PHARMAESSENTIA CORPORATION	-0.71%	-4.11%	+243.99%	+423.83%	18.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.32%	-0.95%	+14.80%	+515.88%	16.53B
EXELIXIS, INC.	+1.53%	+3.49%	+40.68%	+151.75%	13.16B
Average	-0.14%	+2.60%	+56.92%	+197.61%	31.17B
Weighted average by Cap.	-0.00%	+4.97%	+57.08%	+164.21%

	2026 *	2027 *
Net sales	-	38.93M 33.63M 31.64M 28.76M 54.08M 3.73B 54.88M 371M 145M 1.87B 146M 143M 6.21B
Net income	-	-
Net Debt	96.08M 82.98M 78.08M 70.96M 133M 9.21B 135M 916M 359M 4.6B 361M 353M 15.34B	125M 108M 102M 92.27M 174M 11.97B 176M 1.19B 467M 5.99B 469M 459M 19.94B

End-of-day quote OTC Bulletin Board
- ^USD	-